Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D1002 with OxyContin in moderate to severe cancer pain
NCT05265052Phase 2Not yet recruiting
- Sponsor
- 3D Medicines Inc.
- Start
- Dec 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of 3D1002 in cancer pain, sponsored by 3D Medicines Inc.. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
3D1002
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT05265052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265052.